Antibodies

  • Adal­i­mumab
  • Alem­tuzumab
  • Beva­cizumab
  • Cetux­imab
  • Deno­sumab
  • Eculizumab
  • Goli­mumab
  • Inflix­imab
  • Ipil­i­mumab
  • Natal­izumab
  • Nivolumab
  • Omal­izumab
  • Pembrolizumab
  • Pertuzumab
  • Ramu­cirumab
  • Ranibizumab
  • Ritux­imab
  • Tocilizumab
  • Tratuzumab
  • Ustek­inumab

Adal­i­mumab

Adal­i­mumab (Humira®) is a human mono­clonal IgG1/​kappa anti­body indi­cated for the treat­ment of e.g. rheuma­toid arthritis, psori­atic arthritis, or Crohn’s disease. Humira®was the third tumor necrosis factor (TNF) ‑α inhibitor on the market, but the first fully human anti­body directed towards this target. Adal­i­mumab consists of a tetramer of two heavy and two light chains with one N‑glycosylation site per heavy chain. The patent of the orig­i­nator owned by AbbVie expired in 2016 in the US and in the EU in 2018; however, in the last few years AbbVie has secured about 70 (US) patents covering Humira® formu­la­tions, manu­fac­turing tech­niques and methods to treat multiple diseases. These addi­tional patents expire between 2022 and 2034 and AbbVie pursued liti­ga­tion to keep biosim­i­lars off the US market until at least 2022. Learn more

Alem­tuzumab

Alem­tuzumab (Lemtrada®) depletes circu­lating T- and B‑cells through anti­body-depen­dent cellular cytol­ysis and comple­ment-medi­ated lysis. Alem­tuzumab was orig­i­nally indi­cated for second-line treat­ment of chronic lympho­cytic leukemia (CLL), cuta­neous T‑cell lymphoma (CTCL) and normal T‑cell lymphoma under trade names Campath®, MabCam­path® and Campath-1H®. Currently it is indi­cated for the treat­ment of multiple scle­rosis as Lemtrada®. It is also applied for some condi­tioning regi­mens for bone marrow trans­plan­ta­tion, kidney trans­plan­ta­tion, and islet cell trans­plan­ta­tion. Basic patents for Lemtrada® already expired in 2017. Learn more

Beva­cizumab

Beva­cizumab (Avastin®) is a human­ized mono­clonal IgG1/​kappa anti­body that inhibits vascular endothe­lial growth factor A (VEGF‑A) and is used to treat various cancers including colorectal, lung, breast, kidney, and glioblas­tomas. Avastin® patents expired in 2019 in the US and will expire in the EU in 2022. Learn more

Cetux­imab

Cetux­imab (Erbitux®) is an epidermal growth factor receptor (EGFR) inhibitor indi­cated for the treat­ment of certain types of metastatic colorectal cancer, metastatic non-small cell lung cancer and head and neck cancer with or without radio­therapy or plat­inum-based chemotherapy. It is a chimeric mouse/​human mono­clonal anti­body. The main patents for cetux­imab expired in the EU in 2014 and in the US in 2016. Learn more

Deno­sumab

Deno­sumab (Prolia® Xgeva®) is a human mono­clonal anti­body indi­cated for the treat­ment of patients with osteo­porosis at high risk for frac­ture, giant cell tumor of bone, hyper­cal­cemia in malig­nancy and for the preven­tion of skeletal-related events in patients with bone metas­tases from solid tumors. It is the first FDA approved receptor acti­vator of nuclear factor kappa‑B ligand (RANKL) inhibitor. RANKL has been iden­ti­fied to affect the immune system and control bone regen­er­a­tion and remod­eling. Expiry dates of basic Prolia® patents related to the anti­body and treat­ment of patients range from 2017 to 2023 in US and from 2017 to 2021 in EU. Learn more

Eculizumab

Eculizumab (Soliris®) is a human­ized mono­clonal anti­body. It binds to the comple­ment compo­nent 5 (C5), which is a terminal mole­cule in the comple­ment cascade. Eculizumab inhibits the cleavage of C5 by C5 conver­tase into C5a and C5b and subse­quent gener­a­tion of the terminal comple­ment attack complex C5b‑9. Parox­ysmal nocturnal hemo­glo­bin­uria (PNH) patients are defi­cient in terminal comple­ment inhibitors. Eculizumab thus inhibits terminal comple­ment medi­ated intravas­cular hemol­ysis and there­fore the destruc­tion of erythro­cytes. Soliris® is indi­cated for treat­ment of patients with PNH to reduce hemol­ysis. It is also indi­cated for treat­ment of patients with atyp­ical haemolytic uremic syndrome (aHUS) to inhibit comple­ment medi­ated throm­botic micro-angiopathy. Patents on Soliris® will expire in USA in 2021 and in Europe in 2020. Learn more

Goli­mumab

Goli­mumab (Simponi®) is a fully human anti-tumor necrosis factor (TNF)-α IgG1қ mono­clonal anti­body. Simponi® is indi­cated in adults as an adjunct to methotrexate treat­ment for rheuma­toid arthritis, alone or as an adjunct to methotrexate treat­ment for active psori­atic arthritis and as a single agent for active anky­losing spondylitis and ulcer­a­tive colitis. Patents for Simponi® will expire in 2024 in US as well as in EU. Learn more

Inflix­imab

Inflix­imab (Remi­cade®) is a chimeric (mouse/​human) IgG1/​kappa mono­clonal anti­body. Like etan­er­cept and adal­i­mumab, inflix­imab is a TNF‑α blocker. Remi­cade® is indi­cated for treat­ment of Crohn’s disease, psori­atic arthritis, ulcer­a­tive colitis, psori­asis, anky­losing spondylitis, and rheuma­toid arthritis used together with methotrexate. The main patent of Remi­cade® expired in 2015 (EU) and in US in 2018. J&J (Janssen Biotech), the owner of the orig­i­nator mole­cule is trying to delay the market entry of biosim­i­lars with addi­tional patents, however, is strug­gling to defend their validity at court. Learn more

Ipil­i­mumab

Ipil­i­mumab (Yervoy®) is targeting the immune check­point T‑lym­pho­cyte-asso­ci­ated protein 4 (CTLA‑4). It was the first immune check­point inhibitor to be approved for the treat­ment of cancer. Yervoy® is indi­cated for unre­sectable or metastatic melanoma, as an adju­vant in the treat­ment of cuta­neous melanoma, to treat microsatel­lite-high or mismatch repair defi­cient metastatic colorectal cancer, hepa­to­cel­lular carci­noma, and in combi­na­tion with nivolumab (Opdivo®) for advanced renal cell carci­noma. Yervoy® patents will expire in the US in 2023 and in the EU in 2021. Learn more

Natal­izumab

Natal­izumab (Tysabri®) is a human­ized mono­clonal IgG4 anti­body directed against α4 inte­grin, a cellular adhe­sion mole­cule. It is the first anti­body in the class of selec­tive adhe­sion mole­cule inhibitors. Tysabri® is indi­cated as monotherapy for treat­ment of relapsing forms of multiple scle­rosis (MS) and in adult patients with moder­ately to severely active Crohn’s disease (CD) with evidence of inflam­ma­tion, which have had an inad­e­quate response or intol­er­ance to conven­tional CD ther­a­pies. The Tysabri® patents expired in 2015 in the EU as well as in the US. Learn more

Nivolumab

Nivolumab (Opdivo®) is a fully human mono­clonal IgG4 anti­body. Nivolumab blocks programmed cell death ligand 1 or 2 (PD-L1 or PD-L2) from binding to PD‑1, a protein on the surface of acti­vated T cells. Opdivo® is indi­cated, among other cancer types, as a first- or second- line treat­ment for inop­er­able or metastatic melanoma. This includes advanced non-small cell lung cancer, metastatic melanoma, advanced renal cell carci­noma, squa­mous cell carci­noma of the head and neck. Several patent fami­lies are filed, with expi­ra­tion dates of up to 2027 in US and 2026 in EU. Learn more

Omal­izumab

Omal­izumab (Xolair®) is a recom­bi­nant human­ized IgG1 kappa mono­clonal anti­body, which binds to free human immunoglob­ulin E (IgE) and to membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B lympho­cytes. Xolair® is indi­cated for moderate to severe persis­tent asthma and for chronic idio­pathic urticaria in patients who remain symp­to­matic despite H1 anti­his­t­a­mine treat­ment. Key patents on Xolair® already expired in 2017. Learn more

Pembrolizumab

Pembrolizumab (Keytruda®) is a human­ized mono­clonal IgG4 anti­body and is targeted to the cellular programmed cell death protein ‑1 (PD‑1). Programmed cell death ligand 1 or ligand 2 (PD-L1 or PD-L2) is upreg­u­lated on 40 – 50 % of melanomas and has limited expres­sion other­wise. Both ligands bind to PD‑1, a protein on the surface of acti­vated T‑cells. If PD-L1 binds to PD‑1, a T‑cell becomes inac­tive and inhib­ited from attacking a tumor.The inhibitory effect results from promo­tion of apop­tosis in antigen specific T cells while simul­ta­ne­ously blocking apop­tosis in suppressor T‑cells. Pembrolizumab binds to PD‑1, thus blocks PD-L1 or PD-L2 from binding to PD‑1, and T‑cells can again attack tumor cells. Keytruda® is indi­cated for, among other cancer types (more than 30 indi­ca­tions), melanoma, non-small cell lung cancer, head and neck squa­mous cell cancer, clas­sical Hodgkin lymphoma, gastric cancer, cervical cancer, hepa­to­cel­lular carci­noma, and primary medi­astinal large B‑cell lymphoma. Patents for Keytruda® have expiry dates of up to 2036 in US and 2028 in EU. Learn more

Pertuzumab

Pertuzumab (Perjeta®) is a recom­bi­nant human­ized mono­clonal anti­body that targets the dimer­iza­tion domain II of human epidermal growth factor 2 (HER2) expressed on the cell surface. When HER2 is over-induced and dimer­ized with HER3, cell growth accel­er­ates, which can lead to tumor forma­tion. Whereas similar mAb trastuzumab binds to domain IV of the extra­cel­lular segment of HER2 receptor, pertuzumab binds to domain II located on the oppo­site side. Dimer­iza­tion of HER2 / HER3 and acti­va­tion of signaling path­ways is thus prevented. Perjeta® is approved in combi­na­tion with Herceptin® (trastuzumab) and docetaxel chemotherapy for the treat­ment of HER2-posi­tive metastatic breast cancer not received prior anti-HER2 therapy or chemotherapy for metastatic disease. Patent expiry for Perjeta® will be in 2026 (US) and 2024 (EU). Learn more

Ramu­cirumab

Ramu­cirumab (Cyramza®) is a fully human mono­clonal IgG1 / kappa anti­body. Similar to beva­cizumab, ramu­cirumab inhibits angio­gen­esis (forma­tion of new blood vessels) by binding to a specific epitope on the extra­cel­lular domain of vascular endothe­lial growth factor receptor ‑2 (VEGFR‑2) and blocking the inter­ac­tion of VEGF‑A, VEGF‑C, or VEGF‑D with its recep­tors. Cyramza® is indi­cated for gastric cancer, gastro ‑oesophageal junc­tion adeno- carci­noma, metastatic colorectal cancer, non-small cell lung cancer that has spread to other parts of the body or in patients whose cancer involves muta­tions in EGFRs, and hepa­to­cel­lular carci­noma in patients with a high blood level of alpha feto­pro­tein. Cyramza® patents will expire in the US in November 2025 and in the EU in May 2023. Learn more

Ranibizumab

Ranibizumab (Lucentis®) is a human­ized mono­clonal anti­body frag­ment created from the same parent mouse anti­body as beva­cizumab. It is indi­cated for the treat­ment of neovas­cular (wet) age-related macular degen­er­a­tion, macular edema following retinal vein occlu­sion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovas­cu­lar­iza­tion. Ranibizumab binds to the receptor binding site of active forms of vascular endothe­lial growth factor A (VEGF‑A), including the biolog­i­cally active, cleaved form of this mole­cule, VEGF110. The binding of ranibizumab to VEGF‑A prevents the inter­ac­tion of VEGF‑A with its recep­tors (VEGFR1 and VEGFR2) on the surface of endothe­lial cells, reducing endothe­lial cell prolif­er­a­tion, vascular leakage, and new blood vessel forma­tion. The patents on Lucentis® will expire in the US in 2020 and in the EU in 2022. Learn more

Ritux­imab

Ritux­imab (Rituxan®, MabThera®) is a chimeric IgG1/​kappa mono­clonal anti­body targeting CD20, which is primarily found on the surface of B ‑cells. Ritux­imab destroys both normal and malig­nant B ‑cells that have CD20 on their surfaces, and is there­fore used to treat diseases, which are char­ac­ter­ized by having too many over­ac­tive or dysfunc­tional B ‑cells. Rituxan® is applied for treat­ment of many lymphomas and leukemias, trans­plant rejec­tion and some autoim­mune disor­ders. Rituxan® is also used off-label to treat diffi­cult cases of multiple scle­rosis, systemic lupus erythe­matosus and autoim­mune anemias. Rituxan® patents expired in 2013 in the EU and in 2016 in the US. Learn more

Tocilizumab

Tocilizumab (Actemra®) is a recom­bi­nant human­ized IgG1 mono­clonal anti­body targeting the interleukin‑6 receptor (IL-6R). Tocilizumab recog­nizes both the membrane-bound and the soluble form of IL-6R and thus is able to block IL‑6 func­tions. Actemra / RoActemra® is indi­cated for rheuma­toid arthritis, active poly-artic­ular, juve­nile idio­pathic arthritis, giant cell arteritis, cytokine release syndrome, and systemic scle­rosis. In Japan, it is also approved for treat­ment of Castleman’s disease. The patents on Actemra/​RoActemra® expired in US in 2015 and in Europe in 2017. Learn more

Trastuzumab

Trastuzumab (Herceptin®) is a human­ized mono­clonal anti­body that inter­feres with the human epidermal growth factor 2 (HER2)/neu receptor. The HER2 pathway promotes cell growth and cell divi­sion via HER2 receptor. When HER2 is over-induced and dimer­ized, cell growth accel­er­ates, which can lead to tumor forma­tion. Trastuzumab binds to domain IV of the extra­cel­lular segment of HER2 receptor preventing it from dimer­iza­tion and acti­va­tion of its signaling path­ways. Herceptin® is indi­cated for the treat­ment of HER2-posi­tive metastatic breast cancer patients. It is also approved for adju­vant treat­ment of HER2 over-expressing breast cancer and metastatic gastric cancer. Primary patents for Herceptin® expired in 2014 in EU and in US in 2019. Learn more

Ustek­inumab

Ustek­inumab (Stelara®) is an IgG1 kappa human mono­clonal anti­body. Ustek­inumab blocks inter­leukin IL-12 and IL-23, which acti­vate T helper cells (Th cells). Specif­i­cally it is targeting the p40 shared subunit of IL-12 and IL-23, which subse­quently cannot bind to their distinct recep­tors. Stelara® is indi­cated for treating patients with moderate to severe plaque psori­asis, and also to treat active psori­atic arthritis alone or with methotrexate. In 2016, it was also approved to treat Crohn’s disease. The patent protec­tion for Stelara® will be until 2023 in US and 2024 in EU. Learn more

We Value Your Privacy
We use cookies on our website. Some of them are essential, while others help us to analyze how this website is being used and to allow you to contact us through our website, i.e. use the chat widget. You can change your decision at any time.
Privacy Settings
Statistics
We use these technologies to analyze how this website is being used.
Name Google Analytics, Google Tag Manager
Provider Google Ireland Limited, Gordon House, Barrow Street, Dublin 4, Ireland
Purpose Cookie by Google used for website analytics. Generates statistical data on how the visitor uses the website.
Privacy Policy https://policies.google.com/privacy
Cookie Name _ga, _gat, _gid
Cookie Expiry 2 years

 

Name LinkedIn Corporation
Provider LinkedIn Corporation, 605 W Maude Ave, Sunnyvale, CA 94085, USA
Purpose Cookie by LinkedIn used for website analytics. Generates statistical data on how the visitor uses the website.
Privacy Policy https://www.linkedin.com/legal/privacy-policy
Cookie Name
Cookie Expiry 2 years
Customer Interaction
These technologies will allow you to contact us through our website, i.e. use the chat widget.
Name LiveChat
Provider LiveChat Software S.A., ul. Zwycięska 47, 53-033 Wroclaw, Poland
Purpose Communication with clients via online chat using the API of the chat service LiveChat.
Privacy Policy https://www.livechat.com/legal/privacy-policy/
Cookie Name __lc_cid, __lc_cst
Cookie Expiry 2 years
Essential
Technologies required to enable the core functionality of this website.
Name Cookie Consent
Provider Owner of this website, Imprint
Purpose Saves the visitors preferences selected in the cookie banner.
Cookie Name ws_cookie_consent
Cookie Expiry 1 year